- Home
- ANGH vs RAPT Comparison
ANGH vs RAPT Comparison
Compare ANGH & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- RAPT
- Stock Information
- Founded
- ANGH 2012
- RAPT 2015
- Country
- ANGH United Arab Emirates
- RAPT United States
- Employees
- ANGH N/A
- RAPT N/A
- Industry
- ANGH Telecommunications Equipment
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- RAPT Health Care
- Exchange
- ANGH Nasdaq
- RAPT Nasdaq
- Market Cap
- ANGH 52.2M
- RAPT 59.1M
- IPO Year
- ANGH N/A
- RAPT 2019
- Fundamental
- Price
- ANGH $0.70
- RAPT $1.20
- Analyst Decision
- ANGH
- RAPT Hold
- Analyst Count
- ANGH 0
- RAPT 10
- Target Price
- ANGH N/A
- RAPT $6.00
- AVG Volume (30 Days)
- ANGH 50.9K
- RAPT 9.1M
- Earning Date
- ANGH 01-24-2025
- RAPT 03-06-2025
- Dividend Yield
- ANGH N/A
- RAPT N/A
- EPS Growth
- ANGH N/A
- RAPT N/A
- EPS
- ANGH N/A
- RAPT N/A
- Revenue
- ANGH $52,274,011.00
- RAPT N/A
- Revenue This Year
- ANGH N/A
- RAPT N/A
- Revenue Next Year
- ANGH N/A
- RAPT N/A
- P/E Ratio
- ANGH N/A
- RAPT N/A
- Revenue Growth
- ANGH 13.03
- RAPT N/A
- 52 Week Low
- ANGH $0.62
- RAPT $0.79
- 52 Week High
- ANGH $2.27
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- ANGH 43.81
- RAPT 43.92
- Support Level
- ANGH $0.62
- RAPT $1.07
- Resistance Level
- ANGH $0.83
- RAPT $1.29
- Average True Range (ATR)
- ANGH 0.06
- RAPT 0.17
- MACD
- ANGH -0.01
- RAPT -0.04
- Stochastic Oscillator
- ANGH 36.36
- RAPT 15.43
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.